Real-time, Machine Learning powered biomarker testing for precise, personalized rheumatoid arthritis care.
Rheumasense offers a breakthrough solution in rheumatoid arthritis (RA) management through a proprietary, quantitative biomarker test powered by advanced LC-MS technology and machine learning. Designed to measure RA disease activity in real-time, our solution provides clinicians with precise, objective insights that enhance treatment precision, empowering physicians to make faster, evidence-based therapeutic adjustments.
For patients, this means improved quality of life through targeted, personalized care that adapts as their disease changes. By monitoring biomarkers objectively, Rheumasense enables timely intervention that can reduce joint damage, decrease pain, and prevent disease progression. For those in remote or underserved locations, the test’s telemedicine compatibility ensures that RA patients receive the same high-quality care, wherever they are, giving them freedom and confidence in managing their health.
For doctors and hospitals, Rheumasense offers a diagnostic tool that eliminates much of the subjectivity and guesswork currently inherent in assessing disease activity. With Rheumasense, clinicians have access to reproducible data on RA progression, which enables them to assess therapy effectiveness in real-time, optimize treatment regimens, and ultimately enhance patient outcomes. Hospitals benefit from reduced readmission rates, more effective allocation of resources, and improved patient satisfaction.
What sets Rheumasense apart from competitors is its unique combination of patented biomarker technology and machine learning algorithms, developed and validated in collaboration with leading experts. Our partnerships with renowned institutions, including a joint venture with the Mayo Clinic and support from a European venture partner, underscore our commitment to rigorous standards and cutting-edge innovation. Together, these alliances enable us to bring unparalleled accuracy, speed, and scalability to RA diagnostics, setting a new benchmark for personalized, data-driven chronic disease management.